Last reviewed · How we verify
Advair Diskus
Advair Diskus combines a long-acting beta-2 agonist and an inhaled corticosteroid to relax airway muscles and reduce airway inflammation in asthma and COPD.
Advair Diskus combines a long-acting beta-2 agonist and an inhaled corticosteroid to relax airway muscles and reduce airway inflammation in asthma and COPD. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Advair Diskus |
|---|---|
| Also known as | fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist, LABA, ICS |
| Sponsor | Johns Hopkins University |
| Drug class | Combination inhaled corticosteroid / long-acting beta-2 agonist (ICS/LABA) |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate (inhaled corticosteroid) suppresses airway inflammation by binding glucocorticoid receptors, while salmeterol (long-acting beta-2 agonist) activates beta-2 adrenergic receptors on airway smooth muscle to cause bronchodilation. Together, these agents provide both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Oral candidiasis
- Throat irritation
Key clinical trials
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID (PHASE4)
- Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus® (PHASE3)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
- Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advair Diskus CI brief — competitive landscape report
- Advair Diskus updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI